Natera, Inc. (NTRA) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-27

How it makes money

Natera derives the majority of its $2,306.1 million total revenues from selling its Panorama prenatal, Horizon carrier screening, and Signatera oncology tests.

Natera generates revenues primarily by performing cell-free DNA molecular assays across women's health, oncology, and organ health. Insurance payers reimburse Natera under in-network contracts based on positive coverage determinations, while clinics, patients, and laboratory partners are also billed directly.

In addition to direct laboratory processing, Natera licenses its bioinformatics algorithms through its cloud-based Constellation model. This licensing route yields lower revenue and gross profit per test, but avoids direct laboratory processing costs.

What protects it: the moat

Natera protects its diagnostics business with over 650 issued or pending patents and over 350 peer-reviewed publications.

Natera defends its commercial position through proprietary massively multiplexed polymerase chain reaction assay design and computational algorithms that extract target sequences from minute single-cell DNA fragments.

Its intellectual property portfolio and extensive peer-reviewed trial record establish clinical validity, making it difficult for rival genetic testing providers to displace Natera with physicians and insurance payers.

What growth costs

Natera incurred a net loss of $208.2 million in 2025 while scaling operations to process approximately 3.5 million tests.

Expanding clinical volume requires significant ongoing investment in laboratory operations, direct sales channels, and research. Natera operates central CLIA-certified processing facilities in Austin and San Carlos, alongside a dedicated clinical trial site in Boulder.

To drive adoption across oncology and prenatal markets, Natera maintains an expansive field sales force, runs clinical trials to generate utility data, and funds continuous bioinformatics development.

What could damage it

Operational reliance on Illumina, Inc. for critical sequencers and reagents exposes Natera to supply bottlenecks and patent conflicts with a primary competitor.

Natera depends heavily on Illumina, Inc. to provide the hardware sequencers and chemical reagents required to process its molecular test workflows.

Because Illumina also competes directly against Natera in non-invasive prenatal testing through its subsidiary Verinata Health Inc., any supply restrictions, price escalations, or intellectual property disputes between the two firms could disrupt test processing and severely harm earnings.

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Other companies in Diagnostics & Research